Literature DB >> 23546700

The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA).

Temitope Foster1, Frank A Anania, Dong Li, Ronit Katz, Matthew Budoff.   

Abstract

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is the number one cause of liver disease in the United States. The prevalence rates in African Americans (AA), while significantly lower than other ethnic groups with similar known risk factors, have been quoted as high as 24 %. We aim to determine if the presence of NAFLD in African Americans is associated with lower triglyceride and/or higher HDL-c levels and if NAFLD risk factors in African Americans differ from other ethnic groups.
METHODS: A total of 3,056 participants of the Multi Ethnic Study of Atherosclerosis were included in this study. We utilized the baseline serum, anthropometric and radiographic measurements obtained between 2000 and 2002. NAFLD was defined as liver spleen ratio <1 from CT measurements.
RESULTS: The prevalence of NAFLD was and 11 % in AA. We found that age, education, triglyceride levels, HDL-c levels, waist circumference and HOMA-IR were independent correlates of NAFLD in this population. Among those with NAFLD, AA had significantly lower triglyceride levels than Hispanics [125 mg/dl (95 % CI 107-143) versus 192 mg/dl (95 % CI 169-215), p < 0.001] and Caucasians [185 mg/dl (95 % CI 161-209), p = 0.001]. Serum HDL-c was significantly higher in AA with NAFLD (47 mg/dl; 95 % CI 45-50) when compared to Hispanics (44 mg/dl; 95 % CI 43-66, p = 0.02) and Caucasians (44 mg/dl; 95 % CI 42-46, p = 0.02) with NAFLD.
CONCLUSIONS: This study demonstrated that the clinical correlates of NAFLD in African Americans are similar to the correlates of NAFLD in other ethnic groups. Our data also suggests that when evaluating African Americans for NAFLD risk, lower cutoff values should be used to define abnormal triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23546700      PMCID: PMC3780774          DOI: 10.1007/s10620-013-2652-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  AGA technical review on nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  Ethnicity and nonalcoholic fatty liver disease.

Authors:  Kiran Bambha; Patricia Belt; Maria Abraham; Laura A Wilson; Mark Pabst; Linda Ferrell; Aynur Unalp-Arida; Nathan Bass
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

4.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

Authors:  E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance.

Authors:  G Donati; B Stagni; F Piscaglia; N Venturoli; A M Morselli-Labate; L Rasciti; L Bolondi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 8.  CT of coronary artery disease.

Authors:  U Joseph Schoepf; Christoph R Becker; Bernd M Ohnesorge; E Kent Yucel
Journal:  Radiology       Date:  2004-07       Impact factor: 11.105

9.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

10.  Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Lene Mellemkjaer; Ane Marie Thulstrup; Jørgen H Olsen; John A Baron; Henrik Toft Sørensen
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec
View more
  20 in total

Review 1.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 3.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.

Authors:  William N Hannah; Dawn M Torres; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-12

Review 6.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

7.  Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.

Authors:  Naga Chalasani; K Rajender K Reddy; Robert J Fontana; Huiman Barnhart; Jiezhun Gu; Paul H Hayashi; Jawad Ahmad; Andrew Stolz; Victor Navarro; Jay H Hoofnagle
Journal:  Am J Gastroenterol       Date:  2017-08-01       Impact factor: 10.864

8.  Triglyceride Paradox Is Related to Lipoprotein Size, Visceral Adiposity and Stearoyl-CoA Desaturase Activity in Black Versus White Women.

Authors:  Stephanie T Chung; Celeste K L Cravalho; Abby G Meyers; Amber B Courville; Shanna Yang; Nirupa Rachel Matthan; Lilian Mabundo; Maureen Sampson; Ronald Ouwerkerk; Ahmed M Gharib; Alice H Lichtenstein; Alan T Remaley; Anne E Sumner
Journal:  Circ Res       Date:  2019-10-18       Impact factor: 17.367

9.  Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women.

Authors:  Min Kyung Kim; Chul Woo Ahn; Ji Sun Nam; Shinae Kang; Jong Suk Park; Kyung Rae Kim
Journal:  Menopause       Date:  2015-12       Impact factor: 2.953

10.  Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.

Authors:  Rajalingham Sakthiswary; Grace Yin Lai Chan; Ee Tzun Koh; Khai Pang Leong; Bernard Yu Hor Thong
Journal:  ScientificWorldJournal       Date:  2014-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.